2630 Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices 

driven discovery as a powerful tool to 

elucidate biological processes and better 

characterize the health and health 

consequences of all people. This plan 

also fosters ethical use of new 

methodologies arising from artificial 

intelligence and machine learning. 

The updated Strategic Plan will 

accomplish five overarching goals: 

• Goal 1: Improve Capabilities to 

Sustain the NIH Policy for Data 

Management and Sharing 

• Goal 2: Develop Programs to Enhance 

Human Derived Data for Research 

• Goal 3: Provide New Opportunities in 

Software, Computational Methods, 

and Artificial Intelligence 

• Goal 4: Support for a Federated 

Biomedical Research Data 

Infrastructure 

• Goal 5: Strengthen a Broad 

Community in Data Science 

The complete draft plan is available 

at: https://datascience.nih.gov/sites/ 

default/files/NIH-STRATEGIC-PLANFOR-DATA-SCIENCE-2023-2028-finaldraft.pdf. 

Information Requested 

NIH is requesting public comment 

throughout the scientific research 

community and members of the general 

public for the updated NIH Strategic 

Plan for Data Science. NIH encourages 

organizations (e.g., patient advocacy 

groups, professional organizations) to 

submit a single response reflective of 

the views of the organization or 

membership as a whole. 

Response to this RFI is voluntary. 

Respondents are free to address any or 

all topics listed below, as well as other 

relevant topics, for NIH’s consideration. 

If you choose to provide NIH with this 

information, NIH will not share your 

name and contact information outside of 

NIH unless required by law. 

The NIH seeks comments on any of 

the following topics: 

• The appropriateness of the goals of 

the plan, the strategies and 

implementation tactics proposed to 

achieve them; including potential 

benefits, drawbacks or challenges. 

• Opportunities for NIH to partner to 

achieve these goals. 

• Emerging research needs and 

opportunities that should be added to 

the plan. 

• Any other topic the respondent 

feels is relevant for NIH to consider in 

developing this strategic plan. 

This RFI is for planning purposes 

only and should not be construed as a 

solicitation for applications or 

proposals, or as an obligation in any 

way on the part of the United States 

federal government. The federal 

government will not pay for the 

preparation of any information 

submitted or for the government’s use. 

Additionally, the government cannot 

guarantee the confidentiality of the 

information provided. 

Dated: January 6, 2024. 

Lawrence A. Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2024–00696 Filed 1–12–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Biomedical 

Imaging and Bioengineering; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting of the National 

Institute of Biomedical Imaging and 

Bioengineering Special Emphasis Panel. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Biomedical Imaging and Bioengineering 

Special Emphasis Panel; Brain Initiative 

TMM RFA Review. 

Date: February 15, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Democracy II, Suite 920, 6707 Democracy 

Blvd., Bethesda, MD 20817 (Virtual Meeting). 

Contact Person: Alexander O. 

Komendantov, Ph.D., MS, Scientific Review 

Officer, National Institute of Biomedical 

Imaging and Bioengineering, National 

Institutes of Health, 6707 Democracy Blvd., 

Bethesda, MD 20892, (301) 451–3397, 

alexander.komendantov@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, National Institute of 

Biomedical Imaging and Bioengineering, 

National Institutes of Health.) 

Dated: January 9, 2024. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00627 Filed 1–12–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; 

Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute of 

Diabetes and Digestive and Kidney 

Diseases Special Emphasis Panel, March 

06, 2024, 10:00 a.m. to March 06, 2024, 

04:00 p.m., National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 

6707 Democracy Boulevard, Bethesda, 

MD 20892 which was published in the 

Federal Register on November 07, 2023, 

88 FR 77326. 

This meeting notice is amended to 

change the date from 3/06/2024 to 3/05/ 

2024. The meeting is closed to the 

public. 

Dated: January 9, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00626 Filed 1–12–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Test Concerning Entry of Section 321 

Low-Value Shipments Through the 

Automated Commercial Environment 

(ACE) (Also Known as Entry Type 86); 

Republication With Modifications 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: General notice. 

SUMMARY: This document republishes 

with modifications and supersedes a 

U.S. Customs and Border Protection 

(CBP) notice published in the Federal 

Register on August 13, 2019, 

announcing a test to allow certain lowvalue shipments, including those 

shipments subject to Partner 

Government Agency (PGA) data 

requirements, to be entered by filing a 

new type of informal entry 

electronically in the Automated 

Commercial Environment (ACE). The 

test is known as the ACE Entry Type 86 

Test. This document modifies the ACE 

Entry Type 86 Test to clarify the waiver 

of certain regulations and consequences 

of misconduct by test participants. In 

addition, this document makes minor 

technical changes to the original notice. 

DATES: The ACE Entry Type 86 Test 

commenced September 28, 2019, and 


ddrumheller on DSK120RN23PROD with NOTICES1